VGLL4 Promotes Vascular Endothelium Specification Via TEAD1 in the Vascular Organoids and Human Pluripotent Stem Cells-derived Endothelium Model

Overview

Journal Cell Mol Life Sci

Publisher Springer

Specialty Biology

Date 2023 Jul 19

PMID 37468661

Authors

Yingyi Quan

Minjie Hu

Jiang Jiang

Peifeng Jin

Junming Fan

Ming Li

Xiaofang Fan

Yongsheng Gong

Yang Yang

Yongyu Wang

Affiliations

Soon will be listed here.

Abstract

Background: We have shown that Hippo-YAP signaling pathway plays an important role in endothelial cell differentiation. Vestigial-like family member 4 (VGLL4) has been identified as a YAP inhibitor. However, the exact function of VGLL4 in vascular endothelial cell development remains unclear. In this study, we investigated the role of VGLL4, in human endothelial lineage specification both in 3D vascular organoid and 2D endothelial cell differentiation.

Methods And Results: In this study, we found that VGLL4 was increased during 3D vascular organoids generation and directed differentiation of human embryonic stem cells H1 towards the endothelial lineage. Using inducible ectopic expression of VGLL4 based on the piggyBac system, we proved that overexpression of VGLL4 in H1 promoted vascular organoids generation and endothelial cells differentiation. In contrast, VGLL4 knockdown (heterozygous knockout) of H1 exhibited inhibitory effects. Using bioinformatics analysis and protein immunoprecipitation, we further found that VGLL4 binds to TEAD1 and facilitates the expression of endothelial master transcription factors, including FLI1, to promote endothelial lineage specification. Moreover, TEAD1 overexpression rescued VGLL4 knockdown-mediated negative effects.

Conclusions: In summary, VGLL4 promotes EC lineage specification both in 3D vascular organoid and 2D EC differentiation from pluripotent stem cell, VGLL4 interacts with TEAD1 and facilitates EC key transcription factor, including FLI1, to enhance EC lineage specification.

Citing Articles

FLI-1-driven regulation of endothelial cells in human diseases.

Zhang L, Ge T, Cui J J Transl Med. 2024; 22(1):740.

PMID: 39107790 PMC: 11302838. DOI: 10.1186/s12967-024-05546-4.

The new era of cardiovascular research: revolutionizing cardiovascular research with 3D models in a dish.

Yang Y, Yang H, Kiskin F, Zhang J Med Rev (2021). 2024; 4(1):68-85.

PMID: 38515776 PMC: 10954298. DOI: 10.1515/mr-2023-0059.

Maternal regulates zebrafish epiboly through Yap1 activity.

Camacho-Macorra C, Tabanera N, Sanchez-Bustamante E, Bovolenta P, Cardozo M Front Cell Dev Biol. 2024; 12:1362695.

PMID: 38444829 PMC: 10912589. DOI: 10.3389/fcell.2024.1362695.

References

Wimmer R, Leopoldi A, Aichinger M, Kerjaschki D, Penninger J . Generation of blood vessel organoids from human pluripotent stem cells. Nat Protoc. 2019; 14(11):3082-3100. DOI: 10.1038/s41596-019-0213-z. View

Wernly B, Mirna M, Rezar R, Prodinger C, Jung C, Podesser B . Regenerative Cardiovascular Therapies: Stem Cells and Beyond. Int J Mol Sci. 2019; 20(6). PMC: 6470623. DOI: 10.3390/ijms20061420. View

Xin M, Kim Y, Sutherland L, Qi X, McAnally J, Schwartz R . Regulation of insulin-like growth factor signaling by Yap governs cardiomyocyte proliferation and embryonic heart size. Sci Signal. 2011; 4(196):ra70. PMC: 3440872. DOI: 10.1126/scisignal.2002278. View

Zhang Y, Shen H, Withers H, Yang N, Denson K, Mussell A . VGLL4 Selectively Represses YAP-Dependent Gene Induction and Tumorigenic Phenotypes in Breast Cancer. Sci Rep. 2017; 7(1):6190. PMC: 5522454. DOI: 10.1038/s41598-017-06227-7. View

Jiao S, Li C, Hao Q, Miao H, Zhang L, Li L . VGLL4 targets a TCF4-TEAD4 complex to coregulate Wnt and Hippo signalling in colorectal cancer. Nat Commun. 2017; 8:14058. PMC: 5216127. DOI: 10.1038/ncomms14058. View

Cho H, Kim J, Ahn J, Hong Y, Makinen T, Lim D . YAP and TAZ Negatively Regulate Prox1 During Developmental and Pathologic Lymphangiogenesis. Circ Res. 2018; 124(2):225-242. DOI: 10.1161/CIRCRESAHA.118.313707. View

Zhang W, Xu J, Li J, Guo T, Jiang D, Feng X . The TEA domain family transcription factor TEAD4 represses murine adipogenesis by recruiting the cofactors VGLL4 and CtBP2 into a transcriptional complex. J Biol Chem. 2018; 293(44):17119-17134. PMC: 6222106. DOI: 10.1074/jbc.RA118.003608. View

Wimmer R, Leopoldi A, Aichinger M, Wick N, Hantusch B, Novatchkova M . Human blood vessel organoids as a model of diabetic vasculopathy. Nature. 2019; 565(7740):505-510. PMC: 7116578. DOI: 10.1038/s41586-018-0858-8. View

He J, Bao Q, Yan M, Liang J, Zhu Y, Wang C . The role of Hippo/yes-associated protein signalling in vascular remodelling associated with cardiovascular disease. Br J Pharmacol. 2017; 175(8):1354-1361. PMC: 5866970. DOI: 10.1111/bph.13806. View

10.

Chen Z, Friedrich G, Soriano P . Transcriptional enhancer factor 1 disruption by a retroviral gene trap leads to heart defects and embryonic lethality in mice. Genes Dev. 1994; 8(19):2293-301. DOI: 10.1101/gad.8.19.2293. View

11.

Patsch C, Challet-Meylan L, Thoma E, Urich E, Heckel T, OSullivan J . Generation of vascular endothelial and smooth muscle cells from human pluripotent stem cells. Nat Cell Biol. 2015; 17(8):994-1003. PMC: 4566857. DOI: 10.1038/ncb3205. View

12.

Tajonar A, Maehr R, Hu G, Sneddon J, Rivera-Feliciano J, Cohen D . Brief report: VGLL4 is a novel regulator of survival in human embryonic stem cells. Stem Cells. 2013; 31(12):2833-41. PMC: 4617635. DOI: 10.1002/stem.1445. View

13.

Quan Y, Zhang T, Zhang H, Yang J, Jin P, Ma J . Generation of a human embryonic stem cell (WAe001-A-47) with hVGLL4 doxycyclin-inducible expression by the PiggyBac transposon system. Stem Cell Res. 2021; 50:102142. DOI: 10.1016/j.scr.2020.102142. View

14.

Zhang W, Gao Y, Li P, Shi Z, Guo T, Li F . VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex. Cell Res. 2014; 24(3):331-43. PMC: 3945886. DOI: 10.1038/cr.2014.10. View

15.

Wang J, Liu S, Heallen T, Martin J . The Hippo pathway in the heart: pivotal roles in development, disease, and regeneration. Nat Rev Cardiol. 2018; 15(11):672-684. DOI: 10.1038/s41569-018-0063-3. View

16.

Johnson R, Halder G . The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat Rev Drug Discov. 2013; 13(1):63-79. PMC: 4167640. DOI: 10.1038/nrd4161. View

17.

Han X, Liu H, Cai C, Li X, Ju Y, Li Y . Expression of VGLL4 and YAP protein in gastric carcinoma tissues and tumor prognosis. Minerva Med. 2018; 109(6):429-435. DOI: 10.23736/S0026-4806.18.05692-6. View

18.

Wang Z, Quan Y, Hu M, Xu Y, Chen Y, Jin P . VGLL4-TEAD1 promotes vascular smooth muscle cell differentiation from human pluripotent stem cells via TET2. J Mol Cell Cardiol. 2023; 176:21-32. DOI: 10.1016/j.yjmcc.2023.01.005. View

19.

von Gise A, Lin Z, Schlegelmilch K, Honor L, Pan G, Buck J . YAP1, the nuclear target of Hippo signaling, stimulates heart growth through cardiomyocyte proliferation but not hypertrophy. Proc Natl Acad Sci U S A. 2012; 109(7):2394-9. PMC: 3289361. DOI: 10.1073/pnas.1116136109. View

20.

Suo J, Feng X, Li J, Wang J, Wang Z, Zhang L . VGLL4 promotes osteoblast differentiation by antagonizing TEADs-inhibited Runx2 transcription. Sci Adv. 2020; 6(43). PMC: 7608831. DOI: 10.1126/sciadv.aba4147. View